Brief: UNITY Biotech Announces Results From Phase 2 Envision Study Of UBX1325

Unity Biotechnology

27/03/2023 12:33

March 27 (Reuters) - UNITY Biotechnology Inc  UBX.O :
    * UNITY BIOTECHNOLOGY ANNOUNCES RESULTS FROM PHASE 2
ENVISION
STUDY OF UBX1325 IN PATIENTS WITH WET AGE-RELATED MACULAR
DEGENERATION
    * UNITY BIOTECHNOLOGY - UBX1325 MONOTHERAPY DID NOT ACHIEVE
NON-INFERIORITY THROUGH 24 WEEKS
    * UNITY BIOTECHNOLOGY INC - UBX1325 MAINTAINED VISUAL ACUITY
IN
PATIENTS WITH ONGOING ACTIVE DISEASE THROUGH 24 WEEKS
    * UNITY BIOTECHNOLOGY INC - 52% OF UBX1325-TREATED PATIENTS
DID
NOT REQUIRE ANTI-VEGF TREATMENT THROUGH 24 WEEKS
    * UNITY BIOTECHNOLOGY INC - TO SHARE 48-WEEK BEHOLD DME DATA
IN
APRIL AND INTENDS TO INITIATE PHASE 2B STUDY IN DME IN SECOND
HALF OF 2023

Source text for Eikon:  ID:nGNX2k0zhw 
Further company coverage:  UBX.O 

 ((Reuters.Briefs@thomsonreuters.com;))